Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Frontline tyrosine kinase inhibitor selection influences eventual treatment-free remission eligibility and sustained treatment-free remission: A registry analysis of patients treated at CML referral sites in Australia

View Full Paper
Ask AI
Bookmark
Share

Authors

DRDavid Ross

Discussion

Loading...

Member takes

Overview

Registry analysis reveals that selecting frontline TKI influences treatment-free remission eligibility in chronic myeloid leukemia patients.

Key Points

  • To investigate factors affecting treatment-free remission eligibility and sustained treatment-free remission in chronic myeloid leukemia patients.
  • Registry analysis of CML patients at two academic centers in South Australia
  • Included patients receiving primary management and clinical trial participants
  • Criteria for TFR attempt included ≥3 years of TKI therapy and ≥2 years of sustained MR4.5
  • Cumulative incidence of MR4.5 was 75.4% by 12 years
  • 12-year cumulative incidence of TFR eligibility was 56.6%
  • 74% sustained TFR at 12 months in patients treated with frontline second-generation TKIs compared to 50% with imatinib

Cite This Study

David Ross (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e12fhttps://doi.org/10.1182/blood-2025-2008
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictors of successful tirosine kinase inhibitor discontinuation in chronic myeloid leukemia: Long-term, real-world evidence on the role of faster molecular decline and duration of response2025
  2. 2In-depth analysis for TKI-driven real-world management of 201 CML patients using TFR2025 · 2 citations
  3. 3Predictive factors for successful treatment-free remission in patients with chronic myeloid leukemia: A pooled analysis2025
  4. 4Durable treatment-free remission in CML beyond clinical trials: Lessons from a large single-center real-world experience.2026
  5. 5An evaluation of a real-world, multi-disciplinary, treatment-free remission programme for patients with Chronic Myeloid Leukaemia2025